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Background and purpose — Tenosynovial giant cell tumors 
(TGCT) are rare, benign tumors, arising in synovial lining of 
joints, tendon sheaths, or bursae. 2 types are distinguished: 
localized, either digits or extremity, and diffuse lesions. Current 
TGCT incidence is based on 1 single US-county study in 1980, 
with an incidence of 9 and 2 per million person-years in localized 
(including digits) and diffuse TGCT, respectively. We aim to 
determine nationwide and worldwide incidence rates (IR) in 
TGCT affecting digits, localized-extremity TGCT and diffuse-
type TGCT.
Material and methods — Over a 5-year period, the Dutch 
Pathology Registry (PALGA) identifi ed 4,503 pathology 
reports on TGCT. Reports affecting digits were solely used for 
IR calculations. Reports affecting extremities were clinically 
evaluated. Dutch IRs were converted to world population IRs.
Results — 2,815 (68%) digits, 933 (23%) localized-extremity 
and 390 (9%) diffuse-type TGCT were identifi ed. Dutch IR in 
digits, localized-extremity, and diffuse-type TGCT was 34, 11 
and 5 per million person-years, respectively. All 3 groups showed 
a female predilection and highest number of new cases in age 
category 40–59 years. The knee joint was most often affected: 
localized-extremity (46%) and diffuse-type (64%) TGCT, mostly 
treated with open resection: localized (65%) and diffuse (49%). 
Reoperation rate due to local recurrence for localized-extremity 
was 9%, and diffuse TGCT 23%.
Interpretation — This fi rst nationwide study and detailed 
analyses of IRs in TGCT estimated a worldwide IR in digits, 
localized-extremity and diffuse TGCT of 29, 10, and 4 per million 
person-years, respectively. Recurrence rate in diffuse type is 2.6 
times higher, compared with localized extremity. TGCT is still 
considered a rare disease; however, it is more common than 
previously understood. 
■
Tenosynovial giant cell tumors (TGCT) are a rare entity, 
affecting generally young patients (below the age of 40 years), 
with an equal sex distribution. The World Health Organization 
(WHO) classifi cation of Tumors of Soft Tissue and Bone 
(2013) distinguishes 2 TGCT types: localized and diffuse 
lesions (de St. Aubain Somerhausen and van de Rijn 2013). 
Microscopically the 2 types show no clear difference. However, 
on magnetic resonance imaging (MRI) discrimination between 
these types is made (Murphey et al. 2008). 
The localized type was previously described as giant 
cell tumor of tendon sheath, nodular synovitis or localized 
pigmented villonodular synovitis (PVNS). The typical 
macroscopic aspect is a well circumscribed, small (about 
0.5 to 4 centimeters) usually lobulated lesion, with white 
to grey, yellow and brown mottled areas (de St. Aubain 
Somerhausen and van de Rijn 2013). Based on anatomical 
site of the localized-type tumor, differentiation is made into 
a group affecting digits and a group occurring in and around 
larger joints (Ushijima et al. 1986, Chiari et al. 2006). TGCT 
affecting digits is defi ned as a localization distal to metacarpal 
or metatarsal bones; localized-extremity TGCT is defi ned as 
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all sites near joints proximal and including metacarpal and 
metatarsal joints.
In localized TGCT, most lesions are found in the digits of 
hands and feet (Figure 1). The majority of these lesions arise 
from the tendon sheath and less frequently from synovial 
lining of digital joints. Common treatment is marginal excision 
(Verspoor et al. 2013, Stephan et al. 2016). A systematic review 
showed a recurrence rate of 15%, after an average follow-up 
of 37 to 79 months (Fotiadis et al. 2011).
Fewer localized TGCT lesions are found around larger joints; 
they originate from synovial lining, tendon sheaths, or bursae 
(Figure 2). The preferred treatment of these lesions is marginal 
excision by an arthroscopic or an open approach (Verspoor et 
al. 2013, Stephan et al. 2016). A systematic review reported 
an average recurrence rate of 6% after arthroscopic resection 
and 4% after open resection (with variable follow-up) (van der 
Heijden et al. 2013). 
Figure 1. MRI of localized-type TGCT, affecting digits: a 43-year-old 
male patient with a well-circumscribed tumor in the proximal phalanx 
of the third digit of the right hand. Left panel: A coronal T1-weighted 
MRI after intravenous contrast injection. Right panel: A clear coronal 
T1-weighted MRI without intravenous contrast injection.
Figure 2. MRI of TGCT localized-type, extremity: sagittal T1-weighted turbo spin echo MRI of a 
47-year-old female patient, affecting her right knee. A well-circumscribed lesion in Hoffa’s fat pad is 
seen. Left panel: Proton density weighted MRI. Right panel: Pre-saturation inversion recovery MRI.
Figure 3. MRI of diffuse-type TGCT: a 23-year-old male patient with an extensive proliferative syno-
vial process around both cruciate ligaments, dominating the anterior and posterior knee compart-
ments, intra- and extra-articular. Inside suprapatellar pouch and Baker’s cyst a blooming villonodu-
lar aspect shows typical iron depositions. Left panel: Sagittal proton density weighted turbo spin 
echo MRI. Right panel: Sagittal T2-weighted fast fi eld echo MRI.
The diffuse-type TGCT, 
previously called diffuse pigmented 
villonodular synovitis (PVNS) or 
synovitis (villo)nodularis pigmentosa 
(SVP), is a more destructive and 
locally aggressive tumor (Figure 
3). Diffuse TGCT is defi ned by 
the presence of an infi ltrative soft 
tissue mass along synovial lining, 
showing villous projections of the 
proliferated synovial membrane, 
with or without involvement of the 
adjacent joint or other structures. 
Macroscopically, the diffuse type 
affects a large part of synovial 
lining and has a multinodular, multi-
colored appearance, including white, 
yellow and rust-colored areas (de 
St. Aubain Somerhausen and van de 
Rijn 2013). 75% are located around 
the knee joint (van der Heijden et al. 
2013). Current treatment is surgical 
excision (Gonzalez Della Valle 
et al. 2001, Verspoor et al. 2013, 
Stephan et al. 2016). However, it is 
often diffi cult to perform a marginal 
excision. Average recurrence rates 
after arthroscopy are 40% and after 
open resection 14%, with variable 
follow-up times (van der Heijden 
et al. 2013). In extensive disease, 
perioperative radiotherapy might 
reduce recurrence rate (Griffi n 
et al. 2012, Mollon et al. 2015). 
Patients with (multiple) recurrences 
experience impaired quality of life 
(van der Heijden et al. 2014).
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According to the WHO classifi cation of 2002 and 2013, 
the incidence rate (IR) in TGCT is not exactly known (de St. 
Aubain Somerhausen and Dal Cin 2002, de St. Aubain Somer-
hausen and van de Rijn 2013). Current TGCT IRs are based 
on 1 single US-county study completed in 1980, with an IR 
of 9 and 2 per million person-years in localized (including 
digits) and diffuse TGCT, respectively (Myers and Masi 1980). 
Verschoor and coworkers (personal communication 2015) per-
formed the initial nationwide registry based study on giant cell 
containing tumors and calculated an overall IR for TGCT of 50 
per million per year. Discrimination between localized and dif-
fuse disease was not possible as additional clinical information 
was lacking. The difference in biological behavior, however, 
demands further stratifi cation of this general IR in the 3 differ-
ent TGCT groups. Therefore, we aimed to estimate the world-
wide (WHO standardized) TGCT IR by investigating clinical 
data of affected joints, sex differences, 10-year age-specifi c 
categories, initial treatments, follow-up, and recurrence rate at 
individual patient level through extensive additional data col-
lection at participating hospitals. 
Material and methods
Data collection was performed by collaboration of physicians 
from the TGCT study group, and in special collaboration with 
Radboud University Medical Center and Medical Spectrum 
Twente, data collection was performed. Data capturing and 
analyses were performed in the Leiden University Medical 
Center.
A search in PALGA, the non-profi t nationwide network 
and registry of histo- and cytopathology in The Netherlands, 
was performed (Casparie et al. 2007). To fi nd all patients 
with TGCT, between January 2009 and January 2014, the 
search terms ‘Tenosynovial Giant Cell Tumor’, ‘Pigmented 
Villonodular Synovitis’ and a variety of synonyms were used, 
either as a code or as free text (Verschoor 2015, personal 
communication) (Appendix, see Supplementary data). 
Received pathology reports provided limited and anonymous 
information on sex, age, date of tissue removal, and conclusion 
of the pathology report. In these reports, defi nitive diagnosis 
was frequently provided, but information on (localized/diffuse) 
type and affected joint was only sparsely available. Therefore, 
further investigation of additional clinical and radiological 
data was necessary. Reports with TGCT affecting digits were 
solely used for calculating incidence rate (for TGCT digits) 
and not further investigated clinically. PALGA interlinked 
1,941 pathology reports to 95 Dutch hospitals of origin. 
Departments of pathology received a request to collaborate 
in this nationwide study. After approval, personal hospital 
identifi ers were obtained and the departments concerned 
(mostly orthopedics and general surgery) were invited to 
confi rm TGCT diagnosis and add detailed information on 
TGCT type, affected joint, sex, age at fi rst histologically 
proven TGCT, primary treatment, total surgeries related to 
TGCT, date of last follow-up, and follow-up status. Clinical 
and radiographic data were derived from medical fi les. 
Data were kept anonymous. 75 of 95 attributed hospitals 
collaborated, including all specialized and academic centers. 
Clinical evaluation started with 1,941 eligible TGCT cases. 
In 1,576 (81%) cases, diagnosis was confi rmed. 253 reports 
were determined to be in digits and amended in digits group. 
For included extremity TGCT cases (n = 1,323), incomplete 
evaluated clinical data were imputed for unknown data on 
TGCT type (n = 393), affected joint (n = 101), sex (n = 52), age 
(n = 54), and treatment (n = 484), using multiple imputation 
techniques. 10 datasets were imputed, and results were pooled 
according to standard Rubin’s rules (Rubin 1996). All imputed 
data were checked for errors. 
Finally, 1,323 patients with histologically proven TGCT 
were included (Figure 4).
In addition to the 2,562 patients with TGCT affecting digits 
that were already identifi ed based on the pathology reports, 
253 additional patients with TGCT affecting digits were 
discovered during clinical data evaluation. 2,815 patients with 
TGCT affecting digits were identifi ed (2,649 fi ngers, 119 toes, 
47 fi nger or toe), but not investigated in detail. 
Reoperation rate due to local recurrence was defi ned as 
surgery for recurrent TGCT, based on additional pathology 
reports in the same patient, at least 6 months after initial 
surgery until January 2015 (date of PALGA search).
Statistics
The Statistical Package for Social Sciences statistics (SPSS®) 
version 23 (IBM Corp, Armonk, NY, USA) was used for anal-
yses. The IR was separately estimated for localized TGCT, 
either digits or extremity, and diffuse-type TGCT per year, 
by using the number of histologically proven cases of TGCT 
as numerator and the sum of individual person-years for The 
Netherlands as the denominator. IRs were reported for the 







Excluded after clinical 
evaluation (n = 618):
– not TGCT, 326







n = 933 a
Diffuse TGCT
n = 390
Figure 4. Inclusion fl owchart. a Localized TGCT affecting extremities, 
excluding digits.
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affected joints, sex, and 10-year age categories (age at TGCT 
diagnosis). The Central Bureau of Statistics (CBS) provided 
information on Dutch population during the examined period. 
Overall worldwide IRs were obtained by standardizing 
Dutch IRs to global IRs by using the direct method, applying 
age-specifi c IRs in each 10-year age group to the world WHO 
standard population (http://seer.cancer.gov). Estimates of IRs 
were reported with 95% confi dence intervals (CI). Patient 
demographics were reported as counts and percentages for 
categorical variables and as medians and interquartile ranges 
(IQR) for continuous variables. 
The Kaplan–Meier method was used to evaluate reoperation 
due to local-recurrence-free survival at 2 and at 5 years. 
Ethics, funding, and potential confl icts of interest
Research was performed in accordance with the ethical stan-
dards in the 1964 Declaration of Helsinki. As this study does 
not involve subject-related research, it is not covered by Dutch 
law on human subjects research. The study was approved by 
the Institutional Review Board (CME) from our institution 
(registration number G16.024, 22 April 2016). No funding or 
benefi ts were received by any of the authors. There is no con-
fl ict of interest involving any of the authors. 
 
Results
During a 5-year period, 2,815 (68%) digits, 933 (23%) local-
ized-extremity and 390 (9%) diffuse-type TGCT were identi-
fi ed. TGCT affected digits 3 and 7 times more often compared 
with localized-extremity and diffuse TGCT, respectively. 
Dutch TGCT IRs were 34 (CI 33–35) in TGCT affecting 
digits, 11 (CI 11–12) in localized-extremity TGCT and 5 (CI 
4–5) in diffuse-type TGCT per million person-years. Median 
age for TGCT affecting digits was 49 (IQR 38–59) years, for 
localized-extremity TGCT 45 (IQR 34–56) years, and diffuse 
TGCT 47 (IQR 32–61) years. Male:female ratio was about 
1:1.5 for any type.
The Table shows IRs per million person-years for calendar 
years 2009 up to and including 2013, sex, and 10-year age-
specifi c categories of the 3 different TGCT groups. In these 
3 groups: IRs over disaggregated years were quite similar, 
female IRs were slightly higher compared with male IRs, and 
the majority of new cases were seen in age categories 40–49 
and 50–59 years.  
In 2015, The Netherlands counted 16,900,726 inhabitants. 
According to calculated IR, 571 new TGCT affecting digits, 
189 new localized-extremity and 79 new diffuse TGCT 
patients were diagnosed in 2015. The estimated standardized 
worldwide IRs were 29, 10, and 4 per million person-years for 
respectively localized-digits, localized-extremity and diffuse 
TGCT.
As TGCT affecting digits were not clinically investigated, 
the following results were based on localized-extremity and 
diffuse-type TGCT. The majority of TGCT cases affected 
the knee joint; 46% and 64% in localized and diffuse TGCT, 
respectively (Figure 5), followed by the hand and wrist joint 
in localized-type and the ankle and hip joint in diffuse-type 
Incidence rates (IRs) of localized and diffuse-type TGCT in The Netherlands: overall, by calendar year 2009–2013, 
sex and age categories
 
  
 Person-years  Localized TGCT: digits Localized TGCT: extremity Diffuse TGCT
   New cases a IR b New cases a IR b New cases a IR b
            
Overall 83,226,498 2,815 34 (33–35) 933 11 (11–12) 390 5 (4–5)
Calendar year             
 2009 16,485,787    578 35 (32–38) 192 12 (10–13)   73 4 (4–6)
 2010 16,574,989    561 34 (31–37) 183 11 (10–13)   82 5 (4–6)
 2011 16,655,799    580 35 (32–38) 176 11 (9–12)   78 5 (4–6)
 2012 16,730,348    563 34 (31–37) 188 11 (10–13)   77 5 (4–6)
 2013 16,779,575    533 32 (29–35)  194 12 (10–13)   80 5 (4–6)
Sex              
 Female 42,032,934 1,698 (60) 40 (39–42) 544 (58) 13 (12–14) 236 (61) 6 (5–6)
 Male 41,193,564 1,117 (40) 27 (26–29) 389 (42)   9 (9–10) 154 (39) 4 (3–4)
Age at diagnosis             
 0–9 9,528,271      13 (0)   1 (1–2)     6 (1)   1 (0–1)     2 (0) 0 (0–1)
 10–19 10,012,994      98 (3) 10 (8–12)   57 (6)   6 (4–7)   26 (7) 3 (2–4)
 20–29 10,178,289    259 (9) 25 (23–29) 108 (11) 11 (9–13)   49 (13) 5 (4–6)
 30–39 10,673,194    411 (15) 39 (35–42) 169 (18) 16 (14–18)   62 (16) 6 (5–7)
 40–49 12,894,743    650 (23) 50 (47–54) 211 (23) 16 (14–19)   70 (18) 5 (4–7)
 50–59 11,456,662    704 (25) 62 (57–66) 193 (21) 17 (15–19)   71 (18) 6 (5–8)
 60–69 9,466,681    503 (18) 53 (49–58) 133 (14) 14 (12–17)   58 (15) 6 (5–8)
 70–79 5,680,080    155 (6) 27 (23–32)   41 (4)   7 (5–10)   37 (9) 7 (5–9)
 80–89 2,860,556      22 (1)   8 (5–12)   15 (2)   5 (3–9)   15 (4) 5 (3–9)
a New cases: number of cases, %.
b IR = incidence rate per million person-years (95% CI).
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TGCT. Sex distribution per affected joint was comparable.
The initial TGCT treatment plan was open resection in 
65% and 49% in localized and diffuse lesions, respectively 
(Figure 6). TGCT was reported as an incidental fi nding during 
endoprosthetic replacement in 60 procedures.
According to the clinical charts, the majority of patients were 
lost to follow-up in both types (71% in localized and 55% in 
diffuse TGCT). Therefore, we decided to base recurrence rates 
on additional surgeries (defi ned by a second pathology report 
documenting recurrence of TGCT in PALGA). By evaluating 
the municipal personal records database (Gemeentelijke 
BasisAdministratie (GBA)) for all patients, 8 patients (7 
localized and 1 diffuse TGCT) were deceased at time of 
evaluation and were censored at time of death when no second 
surgery was performed.
Reoperation rate due to local recurrence, calculated as a 
percentage from all TGCT patients, in localized TGCT was 
9% and in diffuse TGCT 23%. Reoperation-free survival 
curves for localized and diffuse TGCT are shown in Figure 7. 
In the localized-extremity type, reoperation-free survival at 2 
and at 5 years was 90% and 83%, respectively. In the diffuse 
type, reoperation-free survival at 2 and at 5 years was 77% and 
49%, respectively. 
Only a minority (12%) of TGCT patients were primarily 
treated in a tertiary oncology center: 9% of localized type 
(excluding digits) and 18% of diffuse type.
 
Discussion
Microscopically, localized-extremity and diffuse TGCT 
are identical (de St. Aubain Somerhausen and van de Rijn 
2013). A distinction is made between localized-digits and 
localized-extremity TGCT, based on anatomical location 
and histological differences (Ushijima et al. 1986, Chiari et 
al. 2006). TGCT lesions affecting digits are characterized as 
multiple, small (average 1 centimeter) nodules surrounded by 
a thin fi brous capsule, originating in synovial tissue of tendon 
sheaths or small joints of digits, with a small number of cleft-
like spaces and thick bundles of collagenous tissue, rarely 
showing infl ammatory cells. Conversely, localized-extremity 
TGCT are typically single, relatively large (average 2 centi-
meters) lesions covered by 1 or more layers of synovial cells, 
intra-articular, showing large or numerous pseudoglandular 
spaces sometimes fi lled with foam cells and showing more 
infl am matory cells than digits (Ushijima et al. 1986).
Because of the rarity of the disease, the current TGCT 
literature contains predominantly retrospective, relatively 
small cohort studies, including heterogeneous data (Chiari 
et al. 2006). 2 previous studies described TGCT incidence: 
Myers and Masi (1980) reported 117 new cases of localized 
(including digits) and 49 new cases of diffuse-type TGCT 
between 1960 and 1976, resulting in an IR of 9 per million 
person-years for localized and 2 per million person-years for 
diffuse-type TGCT. A single hospital study was performed by 
Figure 5. Skeleton, showing affected TGCT local-
ization (fi ngers and toes excluded). 3% in localized 













Figure 6. Initial treatment for TGCT 
affecting extremities in The Netherlands, 
excluding digits. 
Figure 7. Reoperation due to local-recur-
rence-free survival curve in localized-
extremity and diffuse TGCT (Kaplan–
Meier), excluding digits. Time zero is time 
of primary surgery. 8 patients died and 
were censored at time of death if a recur-
rence had not occurred.
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Monaghan et al. (2001) and showed an IR of 20 new cases per 
million per year between 1990 and 1997 for localized-type 
TGCT (including digits). Compared with the initial US-county 
study (Myers and Masi 1980), our study showed a 5-fold 
higher IR in localized TGCT (combining localized-digits and 
localized-extremity), and a more than 2.6-fold higher IR in 
diffuse-type TGCT. This difference could be attributed to our 
nationwide coverage, our registry-based clinically verifi ed 
character and because of increased knowledge about the 
disease.
Localized and diffuse lesions are distinguished clinically 
and on MRI. To investigate these lesions separately, clinical 
and radiological confi rmation is of utmost importance. Treat-
ment in localized TGCT affecting digits or extremity is mostly 
1 single excision. In contrast, multiple mutilating surgeries 
are often required for diffuse-type TGCT, with a continuous 
risk of recurrences. In an effort to fi nd all TGCT patients, our 
search included specifi c pathology codes for TGCT and both 
TGCT and synonyms of TGCT as free text (Appendix). There-
fore, cases with “synovitis” or differential diagnostic TGCT 
were also represented in our search. In addition, PALGA data 
are based on input of physicians and sometimes lack speci-
fi city. For instance, affected joint: “upper extremity”, “hand”, 
or “wrist” could all turn out, after clinical evaluation, to be 
affected digits. 
In our search, 1,941 patients were clinically evaluated 
and 1,323 ascertained histologically proven TGCT extrem-
ity cases were included. Consequently, only 68% of eligible 
TGCT patients had histologically proven TGCT of the large 
joints. Without clinical TGCT confi rmation, the estimated IR 
would have been much higher.
Despite our large number of patients with lack of follow-
up, reoperation rates due to local recurrence were described, 
based on additional surgeries, defi ned by a second pathol-
ogy report documenting recurrence of TGCT in PALGA 
(up to January 2015, the date when the PALGA search was 
performed). Recurrences without treatment (no additional 
pathology report) were not included, therefore reoperation 
rate due to recurrence is not identical to recurrence rate. 
However, compared with the literature, we found comparable 
average recurrence rates for localized-extremity TGCT (9%) 
and for diffuse-type TGCT (23%) (van der Heijden et al. 
2013). As local recurrence might develop years after initial 
surgery (Verspoor et al. 2014), and PALGA provided pathol-
ogy reports with a maximum time of 7 years after initial sur-
gery, underestimation of the true recurrence-free survival is 
likely.
There are some limitations to this study. Determined IR may 
be exposed to under- or overestimation. Primarily, our calcu-
lated IR could be slightly underestimated, because our study is 
based on a search in PALGA, the nationwide network and reg-
istry of histo- and cytopathology in The Netherlands (Casparie 
et al. 2007). TGCT patients without a biopsy or treatment are 
not represented in this pathology-based cohort. 
Second, our IR in localized-extremity and diffuse-type 
TGCT could be marginally over- or underestimated, because 
21% of eligible TGCT patients were not clinically evalu-
ated and were therefore imputed. Analyses with and with-
out imputed data were comparable. PALGA identifi ed 1,941 
eligible TGCT patients, scattered over 95 Dutch hospitals. 
Regarding different hospital boards, the different departments 
concerned (pathology, orthopedics, general surgery), and dif-
ferent local legislation, it was challenging to evaluate all eli-
gible TGCT patients. 
Third, a clinical distinction between localized-extremity 
and diffuse-type TGCT is diffi cult, especially for clinicians 
not familiar with this rare disease (Flandry et al. 1994). 
Subsequently, an overestimation of IR in localized-digits 
TGCT might be present. IR of digits is based solely on 
PALGA registry numbers, in contrast to localized-extremity 
and diffuse TGCT IRs, which were clinically evaluated.
Global IR were estimated by using a direct standardization 
approach (http://seer.cancer.gov). Even though this is a widely 
accepted method, there is no adjustment for other infl uences in 
global structure or possible risk factors in TGCT.
To calculate prevalence rates, follow-up time and status are 
important. The majority of our investigated patients lacked 
clinical chart follow-up. It seemed unfair to estimate TGCT 
prevalence rates as the proportion of TGCT patients alive 
at the end of 2013 and diagnosed with TGCT: this assumes 
TGCT not to resolve and not to be cured.
In The Netherlands, traditionally, larger orthopedic clinics 
have been treating TGCT or have diagnosed TGCT as an 
incidental fi nding during arthroscopy or endoprosthetic 
replacement. When (severe) complaints occur, patients are 
commonly referred to specialized tertiary sarcoma centers. 
In this study, we investigated primary patients to calculate 
incidence rate. No centralization of care of TGCT in these 
primary patients is shown, with only a minority of 12% 
primarily treated in a tertiary oncology center. Remarkably, 
only 18% of diffuse TGCT was primarily treated in tertiary 
oncology centers.
In summary, this study is the fi rst nationwide study and 
the fi rst to offer detailed analyses of IRs in TGCT. IRs for 
TGCT of digits, localized-extremity and diffuse-type were 
calculated using additional hospital record evaluation of 
patients originally selected from a nationwide pathology 
registry. The worldwide estimated incidence rate in digits, 
localized-extremity, and diffuse TGCT is 29, 10, and 4 per 
million person-years, respectively. Despite high clinical vari-
ability in localized-extremity and diffuse lesions, both types 
show a predilection for the knee joint, a slight predisposition 
in female patients, median age around 47 years at fi rst treat-
ment, and are primarily treated with an open resection. The 
recurrence rate in the diffuse type is 2.6 times higher com-
pared with the localized-extremity type. TGCT is still consid-
ered a rare disease, though is more common than previously 
understood.
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